292 related articles for article (PubMed ID: 16681716)
21. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
22. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
[TBL] [Abstract][Full Text] [Related]
23. Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer.
Tentes AA; Korakianitis OS; Kakolyris S; Kyziridis D; Veliovits D; Karagiozoglou C; Sgouridou E; Moustakas K
Tumori; 2010; 96(3):411-6. PubMed ID: 20845801
[TBL] [Abstract][Full Text] [Related]
24. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.
Tentes AA; Tripsiannis G; Markakidis SK; Karanikiotis CN; Tzegas G; Georgiadis G; Avgidou K
Eur J Surg Oncol; 2003 Feb; 29(1):69-73. PubMed ID: 12559080
[TBL] [Abstract][Full Text] [Related]
25. [Results of cytoreductive surgery for advanced and recurrent ovarian neoplasms and papillary serous carcinomas of the peritoneum].
Ivanov S; Ivanov S
Akush Ginekol (Sofiia); 2004; 43(5):36-8. PubMed ID: 15518283
[TBL] [Abstract][Full Text] [Related]
26. Is complete cytoreductive surgery feasible in this patient with ovarian cancer?
Dessapt AL; Huchon C; Ngo C; Bats AS; Bensaid C; Lecuru F
Surg Oncol; 2016 Sep; 25(3):326-31. PubMed ID: 27566040
[TBL] [Abstract][Full Text] [Related]
27. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
28. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.
Suidan RS; Zhou Q; Iasonos A; O'Cearbhaill RE; Chi DS; Long Roche KC; Tanner EJ; Denesopolis J; Barakat RR; Zivanovic O
Int J Gynecol Cancer; 2015 May; 25(4):599-606. PubMed ID: 25664437
[TBL] [Abstract][Full Text] [Related]
31. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
32. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
Tian WJ; Chi DS; Sehouli J; Tropé CG; Jiang R; Ayhan A; Cormio G; Xing Y; Breitbach GP; Braicu EI; Rabbitt CA; Oksefjell H; Fotopoulou C; Meerpohl HG; du Bois A; Berek JS; Zang RY; Harter P
Ann Surg Oncol; 2012 Feb; 19(2):597-604. PubMed ID: 21732142
[TBL] [Abstract][Full Text] [Related]
33. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.
Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G
Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
[TBL] [Abstract][Full Text] [Related]
35. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
Rufián S; Muñoz-Casares FC; Briceño J; Díaz CJ; Rubio MJ; Ortega R; Ciria R; Morillo M; Aranda E; Muntané J; Pera C
J Surg Oncol; 2006 Sep; 94(4):316-24. PubMed ID: 16917864
[TBL] [Abstract][Full Text] [Related]
36. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer.
Revaux A; Rouzier R; Ballester M; Selle F; Daraï E; Chéreau E
Int J Gynecol Cancer; 2012 Oct; 22(8):1349-54. PubMed ID: 22954783
[TBL] [Abstract][Full Text] [Related]
37. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
38. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
[TBL] [Abstract][Full Text] [Related]
39. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
Cascales Campos P; Gil J; Parrilla P
Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
[TBL] [Abstract][Full Text] [Related]
40. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]